Protective efficacy of IPTi at 12 months of age compared to estimated resistance to SP at Day 14, ITN coverage and incidence of malaria in placebo groups

<p><b>Copyright information:</b></p><p>Taken from "Can changes in malaria transmission intensity explain prolonged protection and contribute to high protective efficacy of intermittent preventive treatment for malaria in infants?"</p><p>http://www.malariajournal.com/content/7/1/54</p><p>Malaria Journal 2008;7():54-54.</p><p>Published online 3 Apr 2008</p><p>PMCID:PMC2323384.</p><p></p

Model predictions of Ifakara Tanzania IPTi study without (A) and including (B) maternal immunity function with different changes in transmission

<p><b>Copyright information:</b></p><p>Taken from "Can changes in malaria transmission intensity explain prolonged protection and contribute to high protective efficacy of intermittent preventive treatment for malaria in infants?"</p><p>http://www.malariajournal.com/content/7/1/54</p><p>Malaria Journal 2008;7():54-54.</p><p>Published online 3 Apr 2008</p><p>PMCID:PMC2323384.</p><p></p

Trial Profile

<p>Trial Profile</p

Kaplan-Meier Survival Curves Showing the Probability of Remaining Free of P. falciparum Infection during the 11 wk of Surveillance

<p>Week 0 of surveillance began in October 2002, 14 d after the third dose of vaccine was administered.</p

Genuine (Left) and Counterfeit (Right) Cotexcin (Dihydroartemisinin) from Tanzania (Photograph by Manuela Sunjio)

<p>Genuine (Left) and Counterfeit (Right) Cotexcin (Dihydroartemisinin) from Tanzania (Photograph by Manuela Sunjio)</p

Genuine (Right) and Counterfeit (Left) Arsumax (Artesunate) from Cameroon (Photograph by Manuela Sunjio)

<p>Note that the genuine Arsumax bears a hologram from Guilin Pharmaceutical, which manufactures the tablets (see <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0030197#sg001" target="_blank">Figure S1</a>). </p